567-06-003 ISMRM Abstract

The QUANTI OBR Phase 3 trial investigating gadoquatrane for contrast-enhanced MRI of the body with up to 60% less gadolinium

Primary: Body - Whole Body Imaging

Secondary: Contrast Mechanisms - Contrast Agents

567-06-003 · Novel Contrast Mechanisms II · Wednesday, 13 May, 4:55 PM–5:50 PM · Digital Posters Row H

Keywords: Diagnostic performance Body MRI Gadolinium Based Contrast Agents Clinical-research Gadoquatrane

Accepted

Petra K Palkowitsch ¹, Viktoriia Fursenko², Alex Liu³, Birte M Hofmann¹, Mark Klemens¹

¹Bayer AG, Berlin, Germany

²Syneos Health LLC, United States of America

³Bayer Pharma R&D, Whippany, United States of America

Presenting Author: Petra K Palkowitsch

Synopsis

Motivation:

Goals:

Approach:

Results:

Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

References

1. Kuwatsuru et al., A multicenter, randomized, controlled, single-blind comparison phase III study to determine the efficacy and safety of gadobutrol 1.0 M versus gadopentetate dimeglumine following single injection in patients referred for contrast-enhanced MRI of the body regions or extremities; J Magn Reson Imaging. 2015 Feb;41(2):404-13

2. Loevner et al., Efficacy and Safety of Gadopiclenol for Contrast-Enhanced MRI of the Central Nervous System: The PICTURE Randomized Clinical Trial; Invest Radiol. 2023 May 1;58(5):307-313.

3. Kuhl et al., Efficacy and Safety of Half-Dose Gadopiclenol versus Full-Dose Gadobutrol for Contrast-enhanced Body MRI; Radiology. 2023 Jul;308(1):e222612. doi: 10.1148/radiol.222612. [doi]

4. Lohrke et al., Preclinical Profile of Gadoquatrane: A Novel Tetrameric, Macrocyclic High Relaxivity Gadolinium-Based Contrast Agent; Invest Radiol. 2022 Oct 1;57(10):629-638.

5. Hofmann et al., Pharmacokinetics, Safety, and Tolerability of the Novel Tetrameric, High-Relaxivity, Macrocyclic Gadolinium-Based Contrast Agent Gadoquatrane in Healthy Adults. Invest Radiol. 2024 Feb 1;59(2):140-149.

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/567-06-003